Vermillion's Q2 Revenues Rise on Increased OVA1 Sales | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market that its second-quarter revenues increased 6 percent year over year as sales volume for its OVA1 flagship diagnostic test rose by the same percentage.

The Austin, Texas-based molecular diagnostics firm brought in total revenues of $321,000 for the three months ended June 30, compared to $304,000 for the second quarter of 2011. Its license revenues, collected from clinical lab firm Quest Diagnostics, were static year over year at $113,000, while its product revenues increased to $208,000 from $191,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.